Dipendra Khadka earned his MS and PhD in Medicine based on Cancer Biology and Immunology research from Wonkwang University School of Medicine, South Korea, and continued as a Postdoctoral Researcher of NADIANBIO Co. Ltd., Wonkwang University School of Medicine, and specializes in the new drug discovery & development for the treatment of cancer and inflammatory-metabolic diseases. He has a special interest in the quality and value of total care for cancer patients. Dr. Khadka is a Nepal Health Council Professional Registered Medical Technologist (NHPC No. A-848 MLT). He has expertise in cancer biology and immunology for the development of novel therapeutic strategies, drug resistance mechanisms to cancer therapies, and use of oncology drugs in preclinical models. He is recently interested to develop drugs for cancer treatment with their adverse side effects like myelosuppression including febrile neutropenia, fatigue, alopecia, cachexia and pain, and the use of big data to improve cancer care. His research focuses on deciphering the pathophysiologic mechanisms of chemotherapy or targeted therapy and immune checkpoint inhibitors in various cancer types with their TME control, cancer immunotherapy- related inflammatory adverse events and their prevention. Furthermore, his goal is to leverage these newfound mechanisms to develop new therapies for cancer models by the regulatory action of DNA damage, PARP/SIRT1 pathway or NAD+ cellular metabolism and other transcriptional factors.